Neglected Tropical Diseases Diagnosis Market Size, Share, Industry, Forecast and outlook (2024-2031)

Neglected Tropical Diseases Diagnosis Market is Segmented By Disease (Dengue, Chikungunya, Rabies, Lymphatic Filariasis, Buruli Ulcer, Leprosy, Others), By Diagnostic Method (Conventional Method, Molecular Method), By Service Type (Centralized Service, Point-of-care Testing), By End-User (Hospitals, Clinical Laboratories, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Neglected Tropical Diseases Diagnosis Market Overview

The Global Neglected Tropical Diseases Diagnosis Market is estimated to reach at a CAGR of 4.3% during the forecast period (2023-2030).  

Neglected tropical diseases (NTDs) are a series of 20 diseases mostly found in tropical areas, where they disproportionately impact poor people, women and children. People suffer from terrible health, societal, and economic effects due to these disorders. POC diagnostic is an approach to identify and possibly quantify a specific analyte. Based on the variety of biomolecular ways to detect specific analytes, POC tests can be classified into immunological tests, nucleic acid-based tests, and other biomarker-based tests.

Neglected Tropical Diseases Diagnosis Market Summary

To Know More Insights - Download Sample

Neglected Tropical Diseases Diagnosis Market Dynamics

Innovative technologies to diagnose Neglected Tropical Diseases are expected to drive market growth.

LAMP (loop-mediated isothermal amplification) due to its sensitivity, specificity, speed, low cost, and tolerance to inhibitors has become the preferred approach, accounting for 60% of all INAAT publications. The use of LAMP technology in diagnosing bacterial, viral, fungal, and parasite illnesses in humans, animals, and plants is well-established. Compared to PCR-based approaches, the simplicity of LAMP makes it excellent for field testing in underdeveloped nations and for developing point-of-care molecular diagnostic tools. A wide range of approaches to integrating LAMP technology into a field-friendly display have been published, including lateral flow dipstick and lab-on-chip layouts, microfluidic-based methods, in combination with metallic nanoparticles, and combination with smartphone-based technology.

Additionally, the World Health Organization (WHO) is looking into how mobile phone technology might help them handle various global public health challenges. In response, the Department of Neglected Tropical Diseases recently transformed a 2018 graphic teaching guide on neglected tropical diseases of the skin (also known as skin NTDs) into an interactive new mobile phone application. This software application will immediately offer information about a certain disease, including clinical symptoms, management, geographic distribution, and a list of possible diagnoses, to health care workers and the general public. Thus, the market is expected to drive in the forecast period from the above statements.

COVID-19 Impact Analysis on Neglected Tropical Diseases Diagnosis Market

The COVID-19 pandemic has moderately impacted healthcare systems and the market. During the pandemic urgent need to develop diagnostics for COVID-19 has resulted in the already under-resourced development and manufacturing of rapid diagnostic tests (RDTs) and molecular tests for many tropical diseases being placed on hold. Contact tracing for all patients with laboratory-confirmed COVID-19 has been one of the strategies adopted by ministries of health to interrupt transmission and curb the incidence. Such an approach is highly successful for other diseases. For instance, early case detection (through contact tracing) and prompt treatment have been the cornerstones in the fight against leprosy. Visceral leishmaniasis elimination programs in the Indian subcontinent have also relied on identifying people with fever through ‘fever camps.’ Thus, integrating COVID-19 testing into local health services, or piggybacking onto certain NTD programs with well-organized testing capabilities, provides a unique opportunity for increasing COVID-19 testing, especially in harder-to-reach populations.

Additionally, Cases are being tracked, and those at risk of SARS-CoV-2 infection are identified using smartphone applications and other phone-based technology. Due to the fragility of the internet network and the common use of smartphones in NTD endemic areas, these technologies may not be practical to implement. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Neglected Tropical Diseases Diagnosis Market Segmentation Analysis

Point-of-care Testing segment is expected to hold the largest market share in neglected tropical diseases diagnosis market

The point-of-care testing segment is expected to dominate in 2020. The segment's growth benefits due to their cost-effectiveness and user-friendliness. Point-of-care (POC) testing services are increasingly employed as diagnostic tools for rapidly detecting neglected tropical diseases in POC settings. The capacity of point-of-care (POC) testing services to give timely actionable information for patient care during a visit to the healthcare system fuels the growth of the neglected tropical diseases diagnosis market. For instance, The Chagas Detect Plus Rapid Test Kit recently received 510K clearance from the US FDA. InBios International created this POCT to treat Chagas disease. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Neglected Tropical Diseases Diagnosis Market Geographical Share

North America region holds the largest market share in the global neglected tropical diseases diagnosis market

In 2020, North America accounted for the highest revenue share. The growing demand for rapid diagnostic tests for the treatment of lymphatic filariasis, increasing awareness among the people, well-established infrastructure, rise in the adoption of point-of-care testing services in the region are some of the factors the market is expected to boost in the forecast period. For instance, PATH and Standard Diagnostics (SD), a global leader in fast diagnostics (bought by Abbott in 2017), collaborated to create three serology-based lateral flow assays that check for exposure to oncho and LF by identifying antibodies. All three tests require only a single drop of blood from a finger prick, making them simpler to perform and more widely accepted. The tests are intended for use in rural areas where tough conditions exist, and they offer results in less than 30 minutes. These tests do not need to be synchronized with mass medication administration because they detect antibodies and can be done at any time of day. SD BIOLINE Lymphatic Filariasis IgG4 test is designed for use in regions where LF is endemic, and this test detects antibodies to Wb123 for LF alone. The Wb123 does not cross-react with Loa loa infections. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Neglected Tropical Diseases Diagnosis Market Companies 

Major key players in the neglected tropical diseases diagnosis market are Abbott Laboratories, Bio-Rad Laboratories, Inc., Coris BioConcept, Genome Diagnostics Pvt. Ltd, InBios International, Inc., Oscar Medicare Pvt Ltd., Thermo Fisher Scientific, Inc., ZeptoMetrix, LLC, Premier Medical Corporation Ltd. and EUROIMMUN Medizinische Labordiagnostika AG.